Medexus Pharmaceuticals Inc (TSE:MDP) has released an update.
Medexus Pharmaceuticals Inc. reports a record revenue of $113.1 million for the fiscal year 2024, marking a 4.6% increase from the previous year, driven by strong sales of Gleolan and Rupall. Despite this overall growth, the company faced a revenue decline in the fourth quarter and a net loss for the year. Medexus also saw a significant increase in their Adjusted EBITDA, rising by 20.9% to $19.5 million, indicating a robust underlying financial performance.
For further insights into TSE:MDP stock, check out TipRanks’ Stock Analysis page.
